Media Articles Related to Fenoldopam
AHA, Hypertension Society Mull a Merger
Source: MedPage Today Cardiology [2016.09.20]
(MedPage Today) -- Heart association would absorb ASH members, activities
Innovative sound therapy treats hypertension and migraine
Source: Headache / Migraine News From Medical News Today [2016.09.17]
A groundbreaking device that aligns the left and right brain using sound alone may reduce the symptoms of migraine, hypertension, and insomnia.
Genetically-modified probiotic may one day treat pulmonary hypertension
Source: Cardiovascular / Cardiology News From Medical News Today [2016.09.15]
An oral, genetically-modified strain of the probiotic Lactobacillus was used to treat rats with high blood pressure in the lungs, which resulted in reduced blood pressure, improved heart...
Hypertension: Releasing the pressure at its source
Source: Hypertension News From Medical News Today [2016.09.07]
Researchers eyeing first new anti-hypertensive drug treatment strategy in more than 15 years.
Source: MedicineNet Alcohol Abuse and Alcoholism Specialty [2016.09.06]
Title: Portal Hypertension
Category: Diseases and Conditions
Created: 1/31/2005 12:00:00 AM
Last Editorial Review: 9/6/2016 12:00:00 AM
Published Studies Related to Fenoldopam
Fenoldopam in critically ill patients with early renal dysfunction. A crossover study. [2011.08]
BACKGROUND: Acute kidney injury is a frequent problem among many critically ill patients, commonly in the context of multiple organ failure and decreased renal perfusion. Its presence conveys a poor prognosis. Currently, effective therapeutic interventions are limited and dopaminergic agonists have been suggested as an option to prevent further damage... CONCLUSIONS: Our study showed that low-dose Fenoldopam increases creatinine clearance in the critically ill with renal insufficiency. Fenoldopam may be a useful drug in ICU patients with early renal dysfunction. (c) 2010 Blackwell Publishing Ltd.
High-dose fenoldopam reduces postoperative neutrophil gelatinase-associated lipocaline and cystatin C levels in pediatric cardiac surgery. [2011.06.29]
INTRODUCTION: The aim of the study was to evaluate the effects of high-dose fenoldopam, a selective dopamine-1 receptor, on renal function and organ perfusion during cardiopulmonary bypass (CPB) in infants with congenital heart disease (CHD)... CONCLUSIONS: The treatment with high-dose fenoldopam during CPB in pediatric patients undergoing cardiac surgery for CHD with biventricular anatomy significantly decreased urinary levels of NGAL and CysC and reduced the use of diuretics and vasodilators during CPB. TRIAL REGISTRATION: Clinical Trial.Gov NCT00982527.
The effect of fenoldopam and dopexamine on cytokine and endotoxin release following on-pump coronary artery bypass grafting: a prospective randomized double-blind trial. [2010.12]
BACKGROUND: Surgical trauma, exposure to an external circuit, and reduced organ perfusion contribute to the systemic inflammatory response following cardiopulmonary bypass (CPB). Reduced splanchnic perfusion causes disruption of the gastrointestinal mucosal barrier and the release of endotoxins. Fenoldopam (a new dopamine 1 receptor agonist) has been shown to be a specific renosplanchnic vasodilator in animal and human studies. We studied the effects of fenoldopam on the systemic inflammatory response and the release of endotoxins after CPB and compared the results with those for dopexamine... CONCLUSION: A partial attenuation in the inflammatory response is possible with fenoldopam infusion. The elevation in serum endotoxin levels was not affected by dopexamine or fenoldopam infusion.
Fenoldopam use in a burn intensive care unit: a retrospective study. [2010.06.24]
ABSTRACT: BACKGROUND: Fenoldopam mesylate is a highly selective dopamine-1 receptor agonist approved for the treatment of hypertensive emergencies that may have a role at low doses in preserving renal function in those at high risk for or with acute kidney injury (AKI). There is no data on low-dose fenoldopam in the burn population. The purpose of our study was to describe our use of low-dose fenoldopam (0.03-0.09 mug/kg/min) infusion in critically ill burn patients with AKI... CONCLUSIONS: These findings suggest that renal function was preserved and that urine output improved without a decrease in systolic blood pressure, increase in vasoactive medication use, or an increase in resuscitation requirement in patients treated with low-dose fenoldopam. A randomized controlled trial is required to establish the efficacy of low-dose fenoldopam in critically ill burn patients with AKI.
Effects of fenoldopam infusion in complex cardiac surgical operations: a prospective, randomized, double-blind, placebo-controlled study. [2010.04]
AIM: Fenoldopam mesylate is a short-acting dopamine-1 agonist that has been suggested to be a possible reno-protective agent in patients undergoing cardiac surgery. The present study is a prospective, randomized, double-blind placebo controlled trial conducted to determine the effects of fenoldopam in a population of patients undergoing complex cardiac operations... CONCLUSION: Fenoldopam improves the quality of perfusion during CPB. In patients receiving catecholamines to treat a postoperative low cardiac output state, fenoldopam significantly improves renal function and prevents AKI and major morbidity.
Clinical Trials Related to Fenoldopam
The Effect of Fenoldopam in Solitary Partial Nephrectomy Surgery [Terminated]
This trial will study the effects of fenoldopam on renal function in patients who have a
single kidney undergoing surgery to remove part of that kidney secondary to renal cell
carcinoma. The investigators will monitor and evaluate throughout the perioperative course
the kidney function. Normally kidney function is predicted to show a worsening followed by
an improvement after surgery.
The investigators want to specifically identify if the use of fenoldopam lessens the injury
to the kidney with this surgery.
Fenoldopam and Acute Renal Failure [Completed]
Patients undergoing cardiac surgery could develop postoperative acute renal failure
requiring renal replacement therapy.
Fenoldopam, already used for patients with hypertensive emergencies, could improve renal
function in critically ill patients with or at risk for acute renal failure.
An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery [Completed]
Patients with abnormal kidney function are at increased risk for complications following
heart surgery, including worsening kidney function possibly requiring dialysis, a prolonged
stay in the critical care unit and hospital, and the increased risk of death. Prior
attempts at kidney protection for heart surgery patients have had mixed results. Two
medicines, fenoldopam and N-acetylcysteine, have been shown to protect kidney function in
other circumstances that cause kidney stress. The purpose of this study is to determine
whether these medications will help to maintain the function of diseased kidneys during
Fenoldopam in Pediatric Cardiac Surgery [Completed]
The purpose of this study is to determine whether fenoldopam infusion during cardiopulmonary
bypass in young children with congenital heart disease is able to reduce indicators of acute
kidney injury (biomarkers reduction, diuresis increase) compared to a control group.
Fenoldopam for Prevention of Acute Kidney Injury [Active, not recruiting]
Patients with acute coronary syndromes (ACS) are at increased risk for acute kidney injury
(AKI) when they undergo urgent/emergency coronary angiography.
The optimal medical treatment for preventing the occurrence of contrast induced - acute
kidney injury is still controversial.
Fenoldopam mesylate is a dopamine A1 receptor agonist that augments renal plasma flow that
has reduced the risk of radiocontrast dye nephropathy in some (but not all) preliminary
Neutrophil gelatinase-associated lipocalin (NGAL) is a new biomarker predictive for AKI
already shown to be useful for earlier diagnosis of contrast induced nephropathy.
The primary objective of this study is to to test the hypothesis that fenoldopam, in
addition to standard treatment, reduce the occurrence of contrast induced - acute kidney
injury in patients with acute coronary syndrome (ACS) undergoing urgent/emergency coronary
angiography and/or percutaneous coronary intervention.